A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W. Pratz(University of Pennsylvania), Mark J. Levis(Sidney Kimmel Cancer Center), B. Douglas Smith(Johns Hopkins University), Vu H. Duong(University of Maryland, Baltimore), Michelle A. Rudek(Dana-Farber Cancer Institute), Ashkan Emadi(University of Maryland, Baltimore), Christopher D. Gocke, Gary L. Rosner(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Judith E. Karp(Emory University), Ivana Gojo(Johns Hopkins University), Maria R. Baer(University of Maryland, Baltimore), Marianna Zahurak(Bloomberg (United States)), Amy E. DeZern(Johns Hopkins University), Jackie Greer(Sidney Kimmel Comprehensive Cancer Center)
Cited by 43
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Increase in<i>Candida krusei</i>Infection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole
|New England Journal of Medicine|1991|947